US FDA News: FDA approves novel treatment to target abnormality in sickle cell disease

FDA granted accelerated approval to Oxbryta (voxelotor) for the treatment of sickle cell disease in adults and pediatric patients 12 years of age and older
Read more: FDA approves novel treatment to target abnormality in sickle cell disease